ArticleOncogene2026
SETDB2 induces abnormal SHP-1 splicing and promotes immunosuppression in hepatocellular carcinoma.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The clinical application of targeted therapy and immune checkpoint inhibitors (ICIs) has significantly improved the survival prognosis of patients with hepatocellular carcinoma (HCC). However, due to the high heterogeneity of HCC, the response rate to immunotherapy is still low, and there is an urgent need to identify reliable biomarkers and potential therapeutic targets to improve the therapeutic benefit. In this study, a patient-derived xenograft (PDX) model of HCC was constructed to compare and analyze the tumor tissues of the immunotherapy responder group and the non-responder group. RNA sequencing and proteomics combined analysis found that histone H3K9 trimethyltransferase SETDB2 was highly expressed in the non-responder group. Functional experiments showed that SETDB2 deficiency could significantly inhibit tumorigenesis, enhance CD8⁺ T cell infiltration, and improve the immune microenvironment. Further mechanistic studies found that SETDB2 shut down the chromatin structure of the promoter region of the splicing factor SRSF1 through H3K9me3 modification, inhibiting its expression, thereby leading to a decrease in the proportion of functional spliceosomes of the immune regulatory factor SHP-1. After the activity of SHP-1 was weakened, the JAK/STAT3 signaling pathway was continuously activated, leading to an enhanced tumor immunosuppressive phenotype. SETDB2 overexpression also promoted the polarization of tumor-associated macrophages M2 and inhibited the function of effector T cells, leading to a decrease in immunotherapy response. This study systematically revealed that SETDB2 regulates SRSF1 expression through an epigenetic mechanism mediated by H3K9me3, thereby driving the SHP-1 spliceosome deviation, activating STAT3 signaling and reshaping the key pathway of the immune microenvironment. The SETDB2/SRSF1/SHP-1/STAT3 axis plays a core role in HCC immune escape, providing a new perspective on the mechanism of resistance to immunotherapy in liver cancer, and providing a theoretical basis and potential biomarkers for the combined epigenetic targeted intervention strategy of ICIs.
Indexed as
Identifiers
41946995What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.